KLRS – kalaris therapeutics, inc. (US:NASDAQ)
Stock Stats
News
Kalaris to Present Phase 1 Clinical Data for TH103 at the Macula Society Annual Meeting
Kalaris Therapeutics (NASDAQ:KLRS) was downgraded by analysts at Wall St
Kalaris Therapeutics (NASDAQ:KLRS) was upgraded by analysts at Chardan Capital to a "strong-buy" rating.
Kalaris Therapeutics (NASDAQ:KLRS) was given a new $19.00 price target on by analysts at Chardan Capital.
Kalaris Therapeutics (NASDAQ:KLRS) was upgraded by analysts at Wall Stre
Top News Gainers
Top News Decliners
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.